Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) has issued an announcement.
NeuroScientific Biopharmaceuticals Ltd announced its acquisition of StemSmart, a patented stem cell technology from Isopogen WA, which is expected to enhance its portfolio and position in regenerative medicine. This acquisition includes a Special Access Program for treating fistulising Crohn’s disease, with promising early results from a Phase 2 trial. The company is also raising $3.5 million to support this expansion and has proposed new appointments to its board, signaling a strategic move to leverage the growing global recognition of stem cell therapies.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Ltd is a company in the biopharmaceutical industry, focusing on developing therapeutic peptides and now expanding into stem cell technology. The company is strategically positioning itself in the regenerative medicine market by acquiring innovative technologies like the StemSmart MSC, which is derived from adult human donor bone marrow.
YTD Price Performance: 16.67%
Average Trading Volume: 165,856
Technical Sentiment Signal: Sell
Current Market Cap: A$5.06M
See more data about NSB stock on TipRanks’ Stock Analysis page.